tbuckley/cabot-search huggingface dataset:
Abstract 1199: Low Serum Magnesium Concentrations Predict Increase in Left Ventricular Mass Over Five Years Independently of Common Cardiovascular Risk Factors: Study of Health in Pomerania
Authors: Thorsten Reffelmann, Marcus Dörr, Till Ittermann, Henry Völzke, Jörg Ruppert, Daniel Robinson, Stephan B Felix
Journal: Circulation (2008)

Increased cardiac left ventricular mass (LVM) is a significant predictor of adverse cardiovascular events. Experimental studies suggest a pathophysiological role of magnesium (Mg ++ ) in the development of arterial hypertension and left ventricular hypertrophy (LVH). Subjects, aged 45 – 79 years, from the population-based, epidemiological, longitudinal “Study of Health in Pomerania” with complete echocardiographic data (n = 1 348 after exclusion of aortic valve disease) were grouped into five quintiles according to serum Mg ++ at baseline (0.790±0.003 mmol/l, mean±SEM). In the lowest Mg ++ -quintile (Mg ++ &lt;&lt;26&gt;0.73 mmol/l), LVM (187.4±3.1 g at baseline) increased by 14.9±1.2 g over the following five years, while in the highest Mg ++ -quintile (Mg ++ &lt;&lt;0.85 mmol/l) LVM (186.7±3.4 g at baseline) decreased by −0.5±2.8 g (p&lt;0.0001 between quintiles). After five years, LVM was significantly higher in the lowest Mg ++ -quintile (LVM: 202.2±3.4 g) in comparison to the highest Mg ++ -quintile (187.2±3.5 g, p&lt;0.003 between quintiles). Mg ++ inversely correlated with the difference in LVM over five years (p&lt;0.0001, females: p&lt;0.002, males: p&lt;0.024) and also with differences in Sokolow-Lyon-index over five years (p&lt;0.01). Unlike age, gender, presence of hypertension or diabetes mellitus, body mass index, smoking status, renal function, high-sensitive C-reactive protein and use of various antihypertensive drugs including diuretics, only Mg ++ (p&lt;0.0001), pulse pressure (p&lt;0.002) and use of β-blockers (p&lt;0.04) were identified as independent predictors of difference in LVM over five years. Hypomagnesemia is one of the strongest predictors of increase in LVM over the following five years. It should initiate decisive preventive measures in subjects prone to developing LVH.
A new 25-gauge instrument system for transconjunctival sutureless vitrectomy surgery1 1The new Transconjunctival Sutureless Vitrectomy System is disclosed to Bausch and Lomb Surgical, St. Louis, MO. The Microsurgery Advanced Design Laboratory (MADLAB) may receive royalties related to the sale of this and other instruments mentioned in the article.
Authors: Gildo Y Fujii, Eugene de Juan, Mark S Humayun, Dante J Pieramici, Tom S Chang, Eugene Ng, Aaron Barnes, Sue Lynn Wu, Drew N Sommerville
Journal: Ophthalmology (2002)
Influence of a Randomized Clinical Trial on Practice by Participating Investigators: Lessons From the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT) fn1fn1To discuss this article on-line, visit the ACC Home Page at www.acc.org/membersand click on the JACC Forum
Authors: Nowamagbe A. Omoigui, Mitchell J. Silver, Lisa A. Rybicki, Monique Rosenthal, Lisa G. Berdan, Karen Pieper, Samuel V. King, Robert M. Califf, Eric J. Topol
Journal: Journal of the American College of Cardiology (1998)
Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy
Authors: J.I. Harper, I. Ahmed, G. Barclay, M. Lacour, P. Hoeger, M.J. Cork, A.Y. Finlay, N.J.E. Wilson, R.A.C. Graham-Brown, J.M. Sowden, A.L. Beard, M.J. Sumner, J. Berth-Jones
Journal: British Journal of Dermatology (2000)

Journal Article Cyclosporin for severe childhood atopic dermatitis: short course versuscontinuous therapy Get access J.I. Harper, J.I. Harper Department of Paediatric Dermatology, Great Ormond Street Hospital for Children, London WC1N 3JH, U.K. J.I.Harper. Search for other works by this author on: Oxford Academic Google Scholar I. Ahmed, I. Ahmed Department of Dermatology, Walsgrave Hospital, Coventry CV2 2DX, U.K. Search for other works by this author on: Oxford Academic Google Scholar G. Barclay, G. Barclay Department of Dermatology, Walsgrave Hospital, Coventry CV2 2DX, U.K. Search for other works by this author on: Oxford Academic Google Scholar M. Lacour, M. Lacour Department of Paediatric Dermatology, Great Ormond Street Hospital for Children, London WC1N 3JH, U.K. Search for other works by this author on: Oxford Academic Google Scholar P. Hoeger, P. Hoeger Department of Paediatric Dermatology, Great Ormond Street Hospital for Children, London WC1N 3JH, U.K. Search for other works by this author on: Oxford Academic Google Scholar M.J. Cork, M.J. Cork Department of Molecular and Genetic Medicine, Royal Hallamshire Hospital, Guildford Street, Sheffield S10 2JF, U.K. Search for other works by this author on: Oxford Academic Google Scholar A.Y. Finlay, A.Y. Finlay Department of Dermatology, University Hospital of Wales, Cardiff CF4 4XW, U.K. Search for other works by this author on: Oxford Academic Google Scholar N.J.E. Wilson, N.J.E. Wilson Department of Dermatology, Royal Liverpool University Hospital, Liverpool L69 3BX, U.K. Search for other works by this author on: Oxford Academic Google Scholar R.A.C. Graham‐Brown, R.A.C. Graham‐Brown Department of Dermatology, The Leicester Royal Infirmary, Leicester LE1 5WW, U.K. Search for other works by this author on: Oxford Academic Google Scholar J.M. Sowden, J.M. Sowden Department of Dermatology, Wrexham Maelor Hospital, Wrexham LL13 7TD, U.K. Search for other works by this author on: Oxford Academic Google Scholar ... Show more A.L. Beard, A.L. Beard Novartis Pharmaceuticals U.K. Ltd, Frimley, Surrey GU16 5SG, U.K. Search for other works by this author on: Oxford Academic Google Scholar M.J. Sumner, M.J. Sumner Novartis Pharmaceuticals U.K. Ltd, Frimley, Surrey GU16 5SG, U.K. Search for other works by this author on: Oxford Academic Google Scholar J. Berth‐Jones J. Berth‐Jones Department of Dermatology, Walsgrave Hospital, Coventry CV2 2DX, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 142, Issue 1, 1 January 2000, Pages 52–58, https://doi.org/10.1046/j.1365-2133.2000.03241.x Published: 01 January 2000
Assessment of tissue biomarkers following anti-CD137 treatment in the EMT-6 mouse tumor model.
Authors: Zenta Tsuchihashi, Beihong Hu, Emel Girit, Anne Lewin, David Shuster, Gennaro Dito, Shujian Wu, Maria Jure-Kunkel
Journal: Cancer Research (2006)

5556  CD137 (4-1BB/TNFRSF9) is a cell surface molecule that transmits a costimulatory signal for antigen-specific activated T-cells, and it also provides modulatory functions to natural killer and dendritic cells. CD137 belongs to the tumor necrosis factor receptor superfamily, and is important for the effective generation of anti-tumor immune responses. Agonistic anti-mouse CD137 antibodies have demonstrated a potent anti-tumor activity in a variety of mouse tumors including EMT-6 (mammary carcinoma) and P815 (plasmacytoma). In this study, we analyzed the effect of an agonistic anti-CD137 antibody (BMS-469492) on various biomarkers by immunohistochemistry (IHC), flow cytometry (FC) and quantitative PCR (qPCR) in the EMT-6 model. The following biomarker changes were observed with BMS-469492 treatment (5 mg/kg) when compared to tumors treated with control immunoglobulin or to untreated tumors. 1) IHC analysis of EMT-6 tumors detected increases of CD4+ and CD8+ tumor infiltrating lymphocytes. 2) FC analysis of lymph nodes detected a decrease of CD4+/CD8+ cell ratio due to the presence of increased number of CD8+ T cells. It also showed an increase of IFN-γ+ CD3+ cells and CD62L+low cells. 3) qPCR analysis of tumor tissues showed the induction of genes associated with effector T-cell functions (CD8β1, CD3δ, IFN-γ, perforin 1 granzyme B) likely reflecting the infiltration of cytolytic CD8+ lymphocytes. Induction of various genes potentially involved in immune suppression (IDO, CTLA-4, FOXP3, PD-1) were also detected. These biomarkers provide valuable insights in understanding the mechanism of anti-tumor immune response induced by BMS-469492.
Abstract P287: Weight misperception and health-related quality of life in Appalachian adolescents
Authors: Jodi L Southerland, Liang Wang, William T Dalton, Deborah L Slawson
Journal: Circulation (2014)

Objective: Weight misperception (overestimation and underestimation) has been linked to health behaviors and overestimation in particular has been associated with higher psychological distress. Less is known about the relation between weight misperceptions and health-related quality of life (HRQoL) particularly among adolescents in Southern Appalachia. Hypothesis: We assessed the hypothesis that weight misperception would be associated with poorer HRQoL outcomes. Methods: Waves 1 (n=544) and 2 (n=965) baseline data collected between 2011-2012 were used from the Team Up for Healthy Living Project, a cluster-randomized trial targeting obesity prevention in adolescents through a cross-peer intervention among Appalachian school children. BMI percentiles for age and sex were calculated using measured height and weight. Participants were classified into 3 groups: (1) accurate weight perception (perceived weight corresponds with actual weight), (2) underestimators (perceived weight less than actual weight), and (3) overestimators (perceived weight more than actual weight). HRQoL was assessed using the 23-item Pediatric QoL Inventory 4.0 (PedsQL TM ). Multiple linear regression was performed with adjustment for age, gender, race/ethnicity and BMI to examine associations between weight misperception and HRQoL. Results: In total, 393 students (26.7%) underestimated their weight and 67 overestimated their weight (4.6%). Univariate analyses showed that compared to accurate perception, underestimation was associated with higher HRQoL in the following areas: total HRQoL score, physical health, psychosocial health, and emotional and social domains (all p&lt;0.05); and overestimation was associated with a lower total HRQoL score and physical health, as well as emotional functioning (all p&lt;0.05). After adjusting for covariates, compared to accurate perception, underestimation was associated with a higher total HRQoL score (β=2.73, P=0.002), physical health (β=3.09, P=0.001), and psychosocial health (β=2.62, P=0.008), as well as emotional (β=3.23, P=0.011) and social (β=2.79, P=0.011) functioning. Conclusion: Contrary to the hypothesized relationship, underestimation was associated with higher HRQoL across all domains except for school functioning among Appalachian adolescents; whereas, overestimation was not associated with HRQoL. Better understanding of these associations will be beneficial in developing interventions to improve adolescents’ health in Appalachia.
Autism Research Coalition
Authors: Tracy Hampton
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 5356: Brca1 Is An Essential Regulator Of Cardiac Function
Authors: Praphulla C Shukla, Krishna K Singh, Fina Lovren, Yi Pan, Guilin Wang, Adrian Quan, Hwee Teoh, Paul Jurasz, Howard Leong-Poi, Lee Errett, Christine Brezden-Masley, William L Stanford, Michael D Schneider, Thomas G Parker, Subodh Verma
Journal: Circulation (2008)

INTRODUCTION: Preservation of structure and function of the myocardium is critically dependent upon improving the survival of existing cardiomyocytes (CM), through strategies that limit CM apoptosis and DNA damage. BRCA1 is a tumor suppressor gene which functions to promote DNA repair, and protect cells against oxidative and genotoxic stress. We hypothesized that BRCA1 is a novel cellular target to limit CM apoptosis, and prevent aberrant cardiac remodeling. METHODS AND RESULTS: Experimental MI in mice caused a profound 16-fold upregulation in BRCA1 expression, which peaked at 72 hours (p&lt;0.01). In vitro gain-of-function experiments demonstrated that Ad-BRCA1 overexpression protected neonatal rat CM against doxorubicin- and H 2 O 2 -induced apoptosis, as assessed by FACS (p&lt;0.01) and activated caspase-3. Ad-BRCA1-expressing CM exhibited a profound reduction in p53 expression in response to doxorubicin and H 2 O 2 . Co-immunoprecipitation studies demonstrated a distinct physical interaction of BRCA1 with p53. Inhibition of p53, with pifithrin-alpha, blocked doxorubicin-induced CM apoptosis in a manner similar to BRCA1, but BRCA1-overexpressing CM, when treated with doxorubicin did not show further reduction with pifithrin-alpha, indicating an essential requirement of BRCA1 to modulate p53. In vivo gain-of-function studies demonstrated that systemic Ad-BRCA1 delivery completely prevented doxorubicin-induced cardiac dysfunction in mice (echocardiography, p&lt;0.01). In vivo loss-of-function studies were performed in CM -specific BRCA1-KO mice (developed using Cre-lox P technology), which demonstrated marked cardiac dysfunction and mortality in response to doxorubicin administration (p&lt; 0.01 vs. WT + Dox). CONCLUSIONS: We report for the first time an essential role of BRCA1 to limit CM apoptosis, and improve cardiac function in response to genotoxic and oxidative stress. Heart specific deletion of BRCA1 promotes severe systolic dysfunction, and limits survival. In addition to the immediate implications for cardiovascular repair, these data may have ramifications for individuals with BRCA1 mutations or cancer syndromes, particularly in the setting of adjuvant chemotherapy.
A novel approach to the management of inflammatory bacille Calmette-Guérin reactions using topical steroids
Authors: M. Afshar, R. Morris-Jones
Journal: British Journal of Dermatology (2011)

Journal Article A novel approach to the management of inflammatory bacille Calmette–Guérin reactions using topical steroids Get access M. Afshar, M. Afshar Department of Dermatology, King’s College Hospital, London, U.K. Search for other works by this author on: Oxford Academic Google Scholar R. Morris‐Jones R. Morris‐Jones Department of Dermatology, King’s College Hospital, London, U.K. Rachael Morris‐Jones. E‐mail: rachael.morris‐jones@nhs.net Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 164, Issue 6, 1 June 2011, Pages 1402–1403, https://doi.org/10.1111/j.1365-2133.2011.10266.x Published: 01 June 2011
Explaining Variations in Hospital Death Rates
Authors: D. A. Redelmeier
Journal: JAMA (1991)

<h3>To the Editor. —</h3> Park et al<sup>1</sup>present a sophisticated analysis describing factors that influence hospital death rate. Such research helps place current assessments of hospital performance in proper perspective. However, their simulation model of randomness may be misleading. By invoking crude age-sex-race estimates of death rate, the article may have exaggerated the element of chance and thereby underestimated the importance of quality of care. Consider a hypothetical cohort of 100 patients with congestive heart failure (Table). The age-sex-race probability ofdeath for each patient is 5%. However, the cohort actually contains 95 patients with an excellent prognosis (probability of death, 1%) and five patients with a dismal prognosis (probability of death, 80%). Calculation using the refined probability estimates yields an expected death rate of five patients. Calculation using the crude age-sex-race probability yields a similar number of deaths. However, the variance of the first estimate would be much
Abstract 3703: PDGFRα up-regulation mediated by Sonic Hedgehog Pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation
Authors: Francesco Sabbatino, Yangyang Wang, Xinhui Wang, Keith T. Flaherty, David Pepin, Giosuè Scognamiglio, Ling Yu, Zachary A. Cooper, Stefano Pepe, John M. Kirkwood, Dennie T. Frederick, Jennifer A. Wargo, Soldano Ferrone, Cristina R. Ferrone
Journal: Cancer Research (2014)

Abstract Control of mutant BRAF(V600E) metastatic melanoma by BRAF inhibitor (BRAF-I) is limited by intrinsic and acquired resistance. Up-regulation of growth factor receptor such as platelet-derived growth factor receptor (PDGFR)β or insulin-like growth factor receptor (IGFR) is among the mechanisms underlying BRAF-I resistance of melanoma cells. Here we demonstrate for the first time that up-regulation of PDGFRα, a growth factor receptor which markedly differs in its functional properties from its family member PDGFRβ, causes BRAF-I resistance in vitro and in vivo. PDGFRα inhibition by PDGFRα-specific short hairpin RNA (shRNAs) and by clinically available PDGFRα inhibitors (sunitinib, imatinib and crenolanib) restores and increases melanoma cells' sensitivity to BRAF-I in vitro and in vivo. This effect reflects the inhibition of ERK and AKT activation which is associated with BRAF-I resistance of melanoma cells. PDGFRα up-regulation is mediated by Sonic Hedgehog Homolog (Shh) pathway activation which is induced by BRAF-I treatment. Similarly to PDGFRα inhibition, Shh inhibition by the novel small molecule LDE225 restores and increases melanoma cells' sensitivity to BRAF-I in vitro and in vivo. These effects are mediated by PDGFRα down-regulation and by inhibition of ERK and AKT activation. The clinical relevance of these data is indicated by the association of PDGFRα up-regulation in melanoma matched biopsies of BRAF-I +/- MEK inhibitor treated patients with shorter time to disease progression and less tumor regression. These findings suggest that monitoring patients for early PDGFRα up-regulation will facilitate the identification of those who may benefit from the treatment with BRAF-I in combination with clinically approved PDGFRα or Shh inhibitors Citation Format: Francesco Sabbatino, Yangyang Wang, Xinhui Wang, Keith T. Flaherty, David Pepin, Giosuè Scognamiglio, Ling Yu, Zachary A. Cooper, Stefano Pepe, John M. Kirkwood, Dennie T. Frederick, Jennifer A. Wargo, Soldano Ferrone, Cristina R. Ferrone. PDGFRα up-regulation mediated by Sonic Hedgehog Pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3703. doi:10.1158/1538-7445.AM2014-3703
BMA calls for risk management approach to stress Juniors set catering standards charter Irish qualifications and the specialist register Defence society paid 67m to defend accused doctors Funds allocated to reduce waiting lists
Authors: Linda Beecham
Journal: BMJ (1998)

The BMA has called on the NHS Executive to adopt a risk management approach to the problem of work related stress among doctors. It wants medical staff to be involved in assessing the workplace pressures which cause stress, anxiety, and burnout.

Last week the association published The Assessment and Management of Work Related Stress in Doctors, which it commissioned from Professor Tom Cox and his colleagues in the department of psychology at the University of Nottingham. In order to test the risk management approach advocated by the Health and Safety Executive the authors undertook case studies in two large district general hospitals. They interviewed a sample of doctors to identify the stress hazards they face. Problems were classified as local or national. Local factors included sleep deprivation in noisy on-call rooms or inadequate provision of meals; poor career counselling; and lack of control over work. National problems included nursing shortages; pressure on beds; and the new business ethos in the NHS.

Commenting on the report, the chairman of the BMA's …
CERVICAL ACTINOMYCOSIS WITH EMBEDDED FOREIGN BODY AND WITHOUT SINUS FORMATION
Authors: Harry F. Klinefelter, William C. Humphries
Journal: Annals of Internal Medicine (1947)

Case Reports1 October 1947CERVICAL ACTINOMYCOSIS WITH EMBEDDED FOREIGN BODY AND WITHOUT SINUS FORMATIONHARRY F. KLINEFELTER JR., WILLIAM C. HUMPHRIESHARRY F. KLINEFELTER JR.Search for more papers by this author, WILLIAM C. HUMPHRIESSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-27-4-638 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptCervicofacial actinomycosis is the most common type of this disease and the type which is most readily amenable to combined medical and surgical treatment. No attempt is made to review the literature; this case is presented because it is interesting, and unusual in that an embedded foreign body was present and no sinus formation developed.CASE REPORTA 30 year old private was admitted to Army Hospital on November 8, 1945 complaining of painless swelling of the glands in the left side of his neck.Family History: Non-contributory.Past History: Patient was born and reared in East Orange, N. J.,... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication July 2, 1946. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byACTINOMYCOSIS: ITS RECOGNITION AND TREATMENT*JOHN COLLINS HARVEY, M.D., JAMES R. CANTRELL, M.D., A. MURRAY FISHER, M.D. 1 October 1947Volume 27, Issue 4Page: 638-640KeywordsActinomycosisInflammation Issue Published: 1 October 1947 PDF downloadLoading ...